Santen Pharmaceutical | Sustainability Performance
Pharmaceutical company specializing in ophthalmic products and treatments.
1890
Japan
1,001 - 5,000 employees
Pharmaceuticals
$1B - 10B in revenue
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#2621
Overallⓘ#142
in Japanⓘ#63
in PharmaceuticalsⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Financial Data
Business performanceCapital & innovationAnalyst projections
Controversy level
- Santen Pharmaceutical Co Ltd, Japanese ophthalmology major, has faced multiple US FDA Form 483 observations at multiple production facilities following the contested 2024 sustained share price volatility amid Asian ophthalmology customer demand normalization, plus periodic Japanese FSA enforcement scrutiny on inadequate disclosure of glaucoma drug customer concentration affecting Japanese institutional shareholders.
Sustainability employees
ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.Total sustainability employees
7-10
ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.